jeuveau®
Temporary relief
of moderate
to severe frown lines
SCHEDULE A BOTOX AND FILLER CONSULTATION TODAY
By submitting this form you agree to be contacted via phone/text/email
MODERN-MADE USING HI-PURE™ TECHNOLOGY
Jeuveau® stops your nerves from telling your facial muscles to flex, temporarily smoothing moderate to severe lines between the brows.
In clinical trials, Jeuveau® was shown to temporarily improve the appearance of moderate to severe frown lines. In US studies, 68% and 70% of Jeuveau® patients had a 2-grade or better physician and patient-rated improvement in frown lines at Day 30.
But that’s not all.
In a study conducted in Europe and Canada, 54% of patients had visible results as early as two days after treatment.*
And at five months after treatment, 38% of patients had visible results with Jeuveau® **
Disclaimer
Results may vary. We are reputable for complete customer satisfaction for completed treatments. No treatment is promised to provide permanent results. A guarantee is neither provided nor implied. Statements estimating treatment duration and the number of treatments required are based on the typical experience of our patients, however individual experiences may vary.
For more important safety information on Jeuveau®, please visit jeuveau.evolus.com
* 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.
** 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.